← All stocks

Arcturus Therapeutics Holdings Inc.

ARCT Net selling

CIK 0001768224 #3570 in the set updated 18 Sep 2026

Bought (120 mo)

$787.85K

out of their own pocket, the only kind of buying there is

Sold (120 mo)

$138.48M

$4.92M on a plan · $440.24K straight out of an exercise

Sold at will

$133.12M

21 of 39 sales

Net

−$137.69M

−$132.33M against sales at will

By person

11 insiders · 54 transactions

32.6×

Joseph E. Payne holds 32.6 times base salary in stock. $24.51M of shares against $750.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Joseph E. Payne last reported holding, valued at $16.56, the price Common Stock was last bought or sold at on the open market here, on 15 Aug 2025.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Ultragenyx Pharmaceutical Inc. entity

Director

—

$124.28M (4)

−$124.28M

1,400,000

4.93%

$23.18M

−41.7%

Chivukula Pad

Chief Scientific Officer & COO

—

$12.16M (32)

−$12.16M

435,334

1.53%

$7.21M

−40.6%

SASSINE ANDY

Chief Financial Officer

$433.16K (5)

$1.60M (1)

−$1.17M

221,764

0.7802%

$3.67M

−7.6%

Kummerfeld Keith C

See Remarks

$20.35K (2)

$440.24K (2) scheduled

−$419.89K

950

0.0033%

$15.73K

—

Payne Joseph E

President and CEO

$170.34K (3)

—

+$170.34K

1,480,097

5.21%

$24.51M

+0.7%

FARRELL PETER C

Director

$99.67K (2)

—

+$99.67K

98,696

0.3472%

$1.63M

+14.2%

Marquet Magda

Director

$64.33K (2)

—

+$64.33K

50,793

0.1787%

$841.03K

+17.7%

BARLOW JAMES F

Director

—

13,131

0.0462%

$217.42K

+31.3%

Markels John

Director

—

3,131

0.0110%

$51.84K

—

Marantz Jing L.

Director

—

3,131

0.0110%

$51.84K

—

HOLMES EDWARD W

Director

—

3,131

0.0110%

$51.84K

—

Individual transactions

Insider

Date

Role

Action

Price

Amount

Ultragenyx Pharmaceutical Inc.

20 May 2020

Director

Exercised, kept

600,000

$16.00

$9.60M

Show all 54 transactions →

What was left out

Form 4 filings counted 137

Amendments (4/A) skipped 1

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 16

Sales straight out of an exercise 2

Sales at will 21

Transactions with no price 0

Shares from compensation/vesting 635,013

Sales filed before the plan box existed 20

History held since 21 Aug 2019